What Aecor Bio does

AecorBio Inc. is an IND-stage biopharmaceutical company headquartered in Menlo Park, California, founded in 2023. The company has developed a proprietary high-throughput peptide drug discovery platform based on targeted protein hydrolysis (SPH) of single proteome sources, generating libraries of 10,000+ diverse peptides. Unlike conventional screening approaches that measure binding affinity, AecorBio identifies hits by measuring gene expression modulation directly, enabling discovery of novel scaffolds chemically distinct from synthetic drug libraries. The company's pipeline targets treatment resistance across oncology, immunology, and neurology, with lead asset FT-002a-O advancing toward IND filing (target Q1 2027) for Castration-Resistant Prostate Cancer by normalizing IREB2-driven iron dysregulation and restoring sensitivity to androgen receptor inhibitors.

The company's portfolio includes three preclinical/IND-enabling programs: FT-002a-O for CRPC (78% tumor reduction vs. enzalutamide alone in preclinical models, NOAEL at 2,000 mg/kg/day), a label extension into platinum-resistant ovarian cancer, MA-022s for steroid-resistant asthma and eosinophilic esophagitis, and Peptide-DRD2 for Restless Leg Syndrome and Parkinson's Disease. AecorBio operates a lean managed services model with world-class CRO, CMC, and regulatory partners, and maintains an IND-enabling clinical collaboration with Stanford University.

AecorBio is pre-revenue and does not commercialize products. Its business model is structured around future pharmaceutical licensing agreements and co-development partnerships with large pharma companies holding androgen receptor inhibitor franchises (J&J, Pfizer, Astellas, Novartis), where FT-002a would be positioned as an additive combination therapy rather than a displacement of existing blockbusters. The company has raised approximately $2.53 million through an SEC-registered offering in 2025 with 20 investors, following an earlier ~$900K seed round in 2023, and is led by CEO & Co-Founder Dr. Bomi Framroze.

Name

Aecor Bio

Legal name

AecorBio Inc.

Website

https://aecorbio.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

AecorBio is a preclinical biopharmaceutical company developing a proprietary high-throughput peptide drug discovery platform targeting treatment resistance mechanisms in oncology, immunology, and neurology, with lead asset FT-002a advancing toward IND filing for castration-resistant prostate cancer.

Ownership category

akta.pro rank

Product category

Peptide Therapeutics / Biopharmaceutical Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Peptide therapeutics
• Oncology drug discovery
• Prostate cancer treatment
• Immunology drug development
• Neurology therapeutics

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Operations, Personnel, Others

Revenue model

1. Pharmaceutical Licensing: Pre-revenue preclinical stage company. Revenue model will likely involve licensing agreements and co-development partnerships with large pharmaceutical companies for their peptide therapeutics pipeline across oncology, immunology, and neurology indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

AecorBio develops novel peptide therapeutics through a proprietary high-throughput peptide drug discovery platform, with lead candidate FT-002a-O targeting treatment resistance in Castration-Resistant Prostate Cancer (CRPC). The company also has preclinical programs MA-022s (steroid-resistant asthma and EoE) and Peptide-DRD2 (Restless Leg Syndrome and Parkinson's Disease). Revenue is generated through pharmaceutical licensing and co-development partnerships with large pharma companies rather than direct product sales.

Product overview

AecorBio is an IND-stage biopharmaceutical company with a novel high-throughput peptide drug discovery platform targeting multiple drug resistance mechanisms across oncology, immunology, and neurology. The company's portfolio includes multiple drug candidates: FT-002a-O is the lead IND-enabling asset for Castration-Resistant Prostate Cancer (CRPC), MA-022s is in preclinical development for steroid-resistant asthma and eosinophilic esophagitis, and Peptide-DRD2 is in optimization for Restless Leg Syndrome and Parkinson's disease. The platform itself employs targeted proteome hydrolysis to generate peptide libraries, screening for gene expression regulation rather than binding affinity.

Differentiator

Problem solved

Functional benefit

Products and services

• FT-002a-O Orally available peptide co-therapeutic for Castration-Resistant Prostate Cancer (CRPC) that normalizes IREB2-driven iron dysregulation in treatment-resistant prostate tumors, restoring sensitivity to androgen deprivation therapy. Demonstrated 78% tumor volume reduction vs. enzalutamide (SOC) alone in a 46-day AR-resistant PC3 orthotopic CRPC model with clean safety profile at all doses tested. Target IND approval Q1 2027 with Phase 1b completion targeted for Q1 2028.
• MA-022s Novel lipopeptide lead drug candidate for Steroid-Resistant Asthma and Eosinophilic Esophagitis (EoE) with a dual mechanism addressing both eosinophilia and non-T2 inflammatory pathways. Target IND approval Q2 2027.
• Peptide-DRD2 Novel peptide for DRD2 gene upregulation being developed as a dopamine agonist augmentation co-treatment targeting Restless Leg Syndrome and Parkinson's Disease. Target IND approval Q2 2028.
• FT-002a-O (Platinum-Resistant Ovarian Cancer Indication) Label extension of FT-002a's mechanism of action (iron normalization) applied to platinum resistance in ovarian cancer. Targets the iron-dependent survival pathway that underpins cisplatin resistance. Target IND approval Q3 2027.

Quantifiable outcome

• 78% tumor volume reduction vs enzalutamide alone in 46-day AR-resistant PC3 orthotopic CRPC model
• +4 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Stanford UniversitycoreStrategic or Co-development PartnerIND-enabling clinical collaboration with Stanford University. Leverages academic partnership for clinical development expertise and site access.
• Discovery and Preclinical CRO PartnerscoreStrategic or Co-development PartnerWorld-class partners across discovery, preclinical CRO, CMC and regulatory strategy. Supports the company's lean, capital-efficient managed services operating model.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Protagonist Therapeutics: Clinical-stage peptide therapeutics platform developing novel constrained and stabilized peptides for hematology, immunology, and oncology. Directly comparable as a peptide-discovery platform with multiple pipeline programs and similar preclinical-to-IND transition profile, though focused on different targets (hepcidin mimetics, IL-17, IL-23).
• Crinetics Pharmaceuticals: Peptide-based therapeutics company developing oral small molecule and peptide candidates for rare endocrine diseases and oncology. Comparable as a peptide therapeutics developer with multiple programs and a focus on oral peptide bioavailability, an area where AecorBio also differentiates (FT-002a achieves ~30% oral bioavailability).
• Rhythm Pharmaceuticals: Commercial-stage peptide therapeutics company targeting melanocortin-4 receptor (MC4R) pathway for rare obesity disorders. Comparable as a focused peptide therapeutics developer with strong management team and clear partnership/licensing DNA, though operating at a more advanced commercial stage.
• Palatin Technologies: Peptide-based therapeutics company developing melanocortin receptor-targeted peptides for sexual dysfunction, obesity, and inflammatory diseases. Comparable as a peptide therapeutics developer with similar size and multi-program pipeline approach, though at a more advanced clinical stage.
• PepGen: Clinical-stage biotech developing peptide conjugates for Duchenne muscular dystrophy and neurological diseases. Comparable as a peptide platform company targeting neurology indications (similar to AecorBio's Peptide-DRD2 program) with novel chemistry approaches.
• ESSA Pharma: Clinical-stage oncology company developing next-generation therapies for prostate cancer, particularly targeting the androgen receptor pathway in treatment-resistant prostate cancer. Direct comparison for the CRPC treatment-resistance use case that AecorBio's FT-002a addresses.
• Zealand Pharma: Danish peptide therapeutics company with multiple marketed products (dasiglucagon, glepaglutide) and pipeline across metabolic and rare diseases. Comparable as an established peptide platform with multi-program pipeline and licensing/co-development orientation similar to AecorBio's strategy.

Emerging players

• Arvinas: Clinical-stage biotech pioneering targeted protein degradation (PROTAC) technology for oncology. Comparable as an emerging oncology company using novel protein-targeting approaches against previously undruggable mechanisms, similar positioning to AecorBio's IREB2/LIP novel target strategy.
• Kura Oncology: Clinical-stage precision oncology company developing menin inhibitors and farnesyltransferase inhibitors for genetically defined cancers. Comparable as a mid-stage oncology company focused on novel mechanisms in solid tumors, with similar partnership/development model to AecorBio.
• Tarsus Pharmaceuticals: Late-stage biotech developing novel therapeutic peptides (lotilaner) for ophthalmic and infectious disease indications. Comparable as a peptide-based therapeutics developer with novel mechanism approaches and multi-program pipeline.

Market position

Weaknesses4 records

Competitive moat4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aecor Bio